Pathophysiology of an origin of BPH - Course of hypotheses and theories, curent reality and perspectives

1. Jepsen JV, Bruskewitz RC. Clinical manifestation and indications for treatment. In: Lepor H. Prostatic Diseases. Philadelphia: WB Saunders 2000: 123–142.

2. Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132(3): 474–479.

3. Roehrborn CG et al. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology and Natural History. Campbell-Walsh Urology, 10th edition. Philadelphia: Saunders 2012: 2570–2610.

4. Tag KY, Cho HJ. Benign Prostatic Hyperplasia: from bench to clonic. Korean J Urol 2012; 53(3): 139–148.

5. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005; 40(3): 121–128.

6. Loeb S, Kettermann A, Carter HB et al. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol 2009; 182(4): 1458–1462.

7. Briganti A, Capitano U, Suardi N et al. Benign Prostatic hyperplasia and its aetiologies. Eur Urol 2009; 8 (Suppl): 865–871.

8. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996; 27(7): 668–675.

9. McConnell JD, 1995. Prostatic growth: new insights into hormonal regulation. Br J Urol 1995; 76 (Suppl 1): 5–10.

10. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5(5): 545–557.

11. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1987; 2 (Suppl): 33–50.

12. McKeehan WL, Adams PS, Rozset MP. Direct mito­genic effects of insulin, epidermal growth factor, gluco­corticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 1984; 44(5): 1998–2010.

13. Thomas JA, Keenan EJ. Effects of estrogens on the prostate. J Androl 1994; 15(2): 97–99.

14. Smith P, Rhodes NP, Ke Y et al. Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostate stromal cells exposed to high concentrations of estradiol. Prostate Cancer Prostatic Dis 2002; 5(2): 105–110.

15. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004; 172(5 Pt 1): 1784–1791.

16. Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433–438.

17. Hammarsten J, Högstedt B, Holthuis N et al. Components of the metabolit syndrome – risk factors for the development of benign prostatic hyperplasia. Prostate Cancor Prostatic Dis 1998; 1(3): 157–162.

18. Ozden C, Ozdal OL, Urgancioglu G et al. The cor­relation between metabolit syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51(1): 199–203.

19. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract ­symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001; 2(4): 297–301.

20. Nandeesha H. Benign prostatic hyperplasia: dietary and metabolit risk factors. Int Urol Nephrol 2008; 40(3): 649–656.

21. McVary KT, Rademaker A, Lloyd GL et al. Autonomic nervous system overactivity in men with lower urinary tract symtoms secondary to benign prostatic hyperplasia. J Urol 2005; 174(4 Pt 1): 1327–1433.

22. Kohnen PW, Drach GW. Patterns of inflamma­tion in prostatic hyperplasia: a histologic and bacterio­logic study. J Urol 1979; 121: 755–760.

23. Potts JM, Pasqualotto FF. Seminal oxidative stress in patients with chronic prostatitis. Andrologia 2003; 35: 304–308.

24. Sanda MG, Beaty TH et al. Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994; 152(1): 115–119.

25. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15(4): 340–345.

26. Shapiro E, Becich MJ, Hartanto V et al. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992; 147(5): 1293–1297.

27. Gup DI, Shapiro E, Baumann M et al. Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate 1989; 15(2): 105–114.

28. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317(10): 599–604.

29. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004; 6 (Suppl 9): S3–S10.

30. Maruschke M, Protzel Ch, Hakenberg O. How to make a diagnosis of benign prostatic disease. Eur Urol 2009; 8 (6 Suppl): 490–495.

31. Elterman DS, Chughtai B, Lee RK et al. Update on phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Rev Urol 2012; ­14(3–4): 79–86.

32. Vyhnánková V, Pacík D. Tadalafil v léčbě LUTS/BPH a ED. Urol List 2013; 11(1): 11–14.

33. Morelli A, Chavalmane AK, Filippi S et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med 2009; 6(1): 91–106.

34. Yassin A, Saad F, Hoesl CE et al. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 2006; 38(1): 1–12.

35. Tarcan T, Azadzoi KM, Siroky MB et al. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998; 82 (Suppl 1): 26–33.